Header Logo

Yehuda Handelsman, MD

TitleClinical Professor
InstitutionCharles R. Drew University of Medicine and Science
DepartmentInternal Medicine
Address1731 E. 120th Street
Los Angeles CA 90059
PhoneNot Available
FaxNot Available
vCardDownload vCard

    Bibliographic
    selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, Gouni-Berthold I, Paiva da Silva Lima G, Handelsman Y, Lewis BS, Ohman EM, Wang H, L?pez JAG, Monsalvo ML, Sabatine MS, Leiter LA. Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516. PMID: 40544474; PMCID: PMC12368373.
      Citations: 1     Fields:    Translation:Humans
    2. DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators . Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care. 2025 Jun 23. PMID: 40550011.
      Citations:    Fields:    
    3. Hakim JP, Handelsman Y, Banerjee T. Use of finerenone in patients with chronic kidney disease at high risk of heart failure. Metabolism. 2025 Aug; 169:156297. PMID: 40368158.
      Citations:    Fields:    Translation:Humans
    4. Lazarus JV, White TM, Allen AM, Pannain S, Alkhouri N, Bansal MB, Charlton M, Fortune BE, Handelsman Y, Isaacs S, Jacobson IM, Kumar S, Manolas MI, Noureddin M, Rinella ME, Terrault N, El-Mohandes A. Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5). PMID: 40331869; PMCID: PMC12055070.
      Citations:    Fields:    
    5. Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators . Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care. 2025 Apr 18. PMID: 40249765.
      Citations:    Fields:    
    6. Masson W, Barbagelata L, Lobo M, Nogueira JP, Handelsman Y. Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421. PMID: 39893110.
      Citations:    Fields:    Translation:Humans
    7. Handelsman Y. Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease. Am J Manag Care. 2024 Dec; 30(10 Suppl):S189-S196. PMID: 39705195.
      Citations:    Fields:    Translation:Humans
    8. Liu L, Ke W, Li H, Li F, Fan G, Kuang J, Ma J, Zhang X, Ji B, Li S, Du Y, Xue Y, Lyu Z, Gao L, Qu S, Shi Y, Yan L, Deng W, Xu C, Dai P, Xu L, Liu J, Wan X, Wei G, Yu S, Hong S, Zhang P, Huang Z, Cao X, Liao Z, Xiao H, Mu Y, Handelsman Y, Li Y. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122. PMID: 39406449; PMCID: PMC11474422.
      Citations: 2     Fields:    Translation:Humans
    9. DeFronzo RA, Auchus RJ, Bancos I, Blonde L, Busch RS, Buse JB, Findling JW, Fonseca VA, Frias JP, Hamidi O, Handelsman Y, Pratley RE, Rosenstock J, Tudor IC, Moraitis AG, Einhorn D. Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121. PMID: 39013654; PMCID: PMC11253743.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    10. Christofides EA, Stankiewicz A, Denham D, Bellido D, Franek E, Nakhle S, Lukaszewicz M, Reed J, C?zar-Le?n V, Kosch C, Karas P, Fitz-Patrick D, Handelsman Y, Warren M, Hollander P, Huffman D, Raskin P, Oroszl?n T, Lillestol M, Ovalle F. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816. PMID: 38876181.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, Greene SJ, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokg?zoglu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 Oct; 159:155931. PMID: 38852020.
      Citations: 17     Fields:    Translation:Humans
    12. Ibrahim M, Ba-Essa EM, Baker J, Cahn A, Ceriello A, Cosentino F, Davies MJ, Eckel RH, Van Gaal L, Gaede P, Handelsman Y, Klein S, Leslie RD, Pozzilli P, Del Prato S, Prattichizzo F, Schnell O, Seferovic PM, Standl E, Thomas A, Tuomilehto J, Valensi P, Umpierrez GE. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755. PMID: 38115715; PMCID: PMC11320716.
      Citations: 1     Fields:    Translation:Humans
    13. Morales J, Handelsman Y. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):161-170. PMID: 37407115.
      Citations: 30     Fields:    Translation:Humans
    14. Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389. PMID: 36669322.
      Citations: 36     Fields:    Translation:Humans
    15. Hamid A, Handelsman Y, Butler J. DCRM Multispecialty Recommendations in Patients With Heart Failure. J Card Fail. 2022 11; 28(11):1642-1645. PMID: 35973620.
      Citations:    Fields:    Translation:Humans
    16. Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022 Aug; 20(8):609-625. PMID: 35876118.
      Citations: 8     Fields:    Translation:Humans
    17. Handelsman Y, Bunch TJ, Rodbard HW, Steinberg BA, Thind M, Bigot G, Konigsberg L, Wieloch M, Kowey PR. Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. J Diabetes Complications. 2022 07; 36(7):108227. PMID: 35717354.
      Citations: 3     Fields:    Translation:HumansAnimalsCTClinical Trials
    18. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101. PMID: 34922811; PMCID: PMC9803322.
      Citations: 22     Fields:    Translation:Humans
    19. Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021 06; 27(6):505-537. PMID: 34116789.
      Citations: 105     Fields:    Translation:Humans
    20. Duprez DA, Handelsman Y, Koren M. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418. PMID: 33116551; PMCID: PMC7548340.
      Citations: 4     Fields:    Translation:Humans
    21. Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224. PMID: 33471721.
      Citations: 92     Fields:    Translation:Humans
    22. Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020 09 22; 142(12):1205-1218. PMID: 32955939.
      Citations: 52     Fields:    Translation:Humans
    23. Handelsman Y, Bloomgarden Z. Paradigm shift in the management of DM & CVD-preventing the next CV event. J Diabetes. 2020 Sep; 12(9):630-632. PMID: 32573096.
      Citations:    Fields:    Translation:Humans
    24. Bloomgarden Z, Handelsman Y. Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. Am J Prev Cardiol. 2020 Mar; 1:100007. PMID: 34327450; PMCID: PMC8315327.
      Citations: 1     
    25. Handelsman Y, Muskiet MHA, Meneilly GS. Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2020 Feb; 37(2):973. PMID: 31873867; PMCID: PMC7004417.
      Citations:    Fields:    
    26. Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617. PMID: 31926059.
      Citations: 26     Fields:    Translation:Humans
    27. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139. PMID: 32022600.
      Citations: 230     Fields:    Translation:Humans
    28. Bloomgarden Z, Handelsman Y. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9. PMID: 31722441.
      Citations:    Fields:    Translation:Humans
    29. Handelsman Y, Muskiet MHA, Meneilly GS. Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2019 12; 36(12):3321-3339. PMID: 31646466; PMCID: PMC6860469.
      Citations: 3     Fields:    Translation:Humans
    30. Handelsman Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586. PMID: 31444707; PMCID: PMC6822830.
      Citations: 7     Fields:    Translation:Humans
    31. Tomaszewski KJ, Allen A, Mocarski M, Schiffman A, Kruger D, Handelsman Y, Heile M, Brod M. Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study. Patient Prefer Adherence. 2019; 13:761-773. PMID: 31190758; PMCID: PMC6520481.
      Citations: 2     
    32. Handelsman Y, Bloomgarden Z. Introduction to the 2nd Heart in Diabetes (HiD) Meeting. J Diabetes. 2019 07; 11(7):599-600. PMID: 31066171.
      Citations:    Fields:    
    33. Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958. PMID: 30953107; PMCID: PMC6509076.
      Citations: 35     Fields:    Translation:Humans
    34. Handelsman Y. Gerald Reaven: A man for our times. Diab Vasc Dis Res. 2019 03; 16(2):113-115. PMID: 31014094.
      Citations:    Fields:    Translation:Humans
    35. Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H, Lopez JAG, Herzog CA, Handelsman Y. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399. PMID: 30697776; PMCID: PMC6712383.
      Citations: 31     Fields:    Translation:Humans
    36. Bloomgarden Z, Einhorn D, Grunberger G, Handelsman Y. Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association? J Diabetes. 2019 05; 11(5):340-341. PMID: 30600643.
      Citations: 4     Fields:    Translation:Humans
    37. Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892. PMID: 30499237; PMCID: PMC6667916.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    38. Bloomgarden Z, Handelsman Y. Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. J Diabetes. 2019 Apr; 11(4):258-260. PMID: 30561080.
      Citations:    Fields:    Translation:Humans
    39. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100. PMID: 30742570.
      Citations: 155     Fields:    Translation:Humans
    40. Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242. PMID: 30600136.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    41. Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011. PMID: 30763128.
      Citations: 44     Fields:    Translation:Humans
    42. Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D. Corrections. J Manag Care Spec Pharm. 2018 Nov; 24(11):1196a. PMID: 30806138; PMCID: PMC10401970.
      Citations:    Fields:    
    43. Lingvay I, Handelsman Y, Linjawi S, Vilsb?ll T, Halladin N, Ranc K, Liebl A. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155. PMID: 30383495.
      Citations: 5     Fields:    Translation:Humans
    44. Cannon A, Handelsman Y, Heile M, Shannon M. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13. PMID: 30156443; PMCID: PMC10408423.
      Citations: 104     Fields:    Translation:Humans
    45. Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29. PMID: 30156445; PMCID: PMC10408429.
      Citations: 8     Fields:    Translation:HumansPHPublic Health
    46. Heile M, Wyne K, Billings LK, Cannon A, Handelsman Y, Shannon M. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52. PMID: 30156446; PMCID: PMC10408396.
      Citations: 6     Fields:    Translation:Humans
    47. Billings LK, Handelsman Y, Heile M, Schneider D, Wyne K. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S30-S41. PMID: 30156447; PMCID: PMC10408424.
      Citations: 11     Fields:    Translation:Humans
    48. Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829. PMID: 29974618; PMCID: PMC6282993.
      Citations: 7     Fields:    Translation:Humans
    49. Bloomgarden Z, Handelsman Y. World congress on insulin resistance, diabetes and cardiovascular disease. J Diabetes. 2018 Oct; 10(10):776-777. PMID: 29971929.
      Citations: 2     Fields:    Translation:Humans
    50. Handelsman Y, Lepor NE. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13). PMID: 29934421; PMCID: PMC6064883.
      Citations: 31     Fields:    Translation:HumansAnimals
    51. Bloomgarden Z, Einhorn D, Handelsman Y, Misra A, Zonszein J, Grunberger G, Jellinger PS, Garber AJ. American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. J Diabetes. 2018 Aug; 10(8):618-620. PMID: 29655268.
      Citations: 1     Fields:    Translation:Humans
    52. Bloomgarden Z, Handelsman Y. Transition from hospital to outpatient diabetes care. J Diabetes. 2018 Jul; 10(7):538-540. PMID: 29655199.
      Citations:    Fields:    Translation:Humans
    53. Grunberger G, Handelsman Y, Bloomgarden ZT, Fonseca VA, Garber AJ, Haas RA, Roberts VL, Umpierrez GE. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. Endocr Pract. 2018 Mar; 24(3):302-308. PMID: 29547046.
      Citations: 21     Fields:    Translation:Humans
    54. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120. PMID: 29368965.
      Citations: 195     Fields:    Translation:Humans
    55. Bloomgarden Z, Handelsman Y. How does CKD affect HbA1c? J Diabetes. 2018 Apr; 10(4):270. PMID: 29124865.
      Citations: 17     Fields:    Translation:Humans
    56. Vinik AI, Camacho PM, Davidson JA, Handelsman Y, Lando HM, Leddy AL, Reddy SK, Cook R, Spallone V, Tesfaye S, Ziegler D, Task Force to Develop an AACE Position Statement on Autonomic Testing. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION. Endocr Pract. 2017 Dec; 23(12):1472-1478. PMID: 29320641.
      Citations: 8     Fields:    Translation:Humans
    57. Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, Handelsman Y, Hirsch IB, Umpierrez GE. AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. Endocr Pract. 2017 Nov; 23(11):1345-1349. PMID: 29190135.
      Citations: 4     Fields:    Translation:Humans
    58. Bloomgarden ZT, Einhorn D, Handelsman Y. Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526-528. Diabetes Care. 2017 10; 40(10):e154. PMID: 28931711.
      Citations:    Fields:    
    59. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950. PMID: 28927706.
      Citations: 219     Fields:    Translation:Humans
    60. Bloomgarden ZT, Kosiborod MN, Handelsman Y. Concomitant Diabetes and Atrial?Fibrillation: No Sugarcoating the Bittersweet Reality. J Am Coll Cardiol. 2017 09 12; 70(11):1336-1338. PMID: 28882230.
      Citations: 1     Fields:    Translation:Humans
    61. Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56. PMID: 28672317; PMCID: PMC5817473.
      Citations: 98     Fields:    Translation:Humans
    62. Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868. PMID: 28548024.
      Citations: 9     Fields:    Translation:Humans
    63. Brown WV, Handelsman Y, Martin SS, Morris PB. JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). J Clin Lipidol. 2017 Jul - Aug; 11(4):846-854. PMID: 28642100.
      Citations:    Fields:    Translation:Humans
    64. Brown WV, Handelsman Y, Martin SS, Morris PB. JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). J Clin Lipidol. 2017 May - Jun; 11(3):587-595. PMID: 28465133.
      Citations:    Fields:    Translation:Humans
    65. Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996. PMID: 28206704; PMCID: PMC5485164.
      Citations: 22     Fields:    Translation:Humans
    66. Bloomgarden ZT, Einhorn D, Handelsman Y. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care. 2017 04; 40(4):526-528. PMID: 28325800.
      Citations: 4     Fields:    
    67. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87. PMID: 28437620.
      Citations: 371     Fields:    Translation:Humans
    68. Bloomgarden Z, Mende C, Einhorn D, Handelsman Y. Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430. PMID: 28133929.
      Citations:    Fields:    Translation:Humans
    69. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497. PMID: 28156151.
      Citations: 59     Fields:    Translation:HumansPHPublic Health
    70. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract. 2017 02; 23(2):207-238. PMID: 28095040.
      Citations: 180     Fields:    Translation:Humans
    71. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255. PMID: 27980006; PMCID: PMC5384660.
      Citations: 279     Fields:    Translation:Humans
    72. Linjawi S, Bode BW, Chaykin LB, Courr?ges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb; 8(1):101-114. PMID: 27943107; PMCID: PMC5306117.
      Citations: 80     
    73. Handelsman Y, Shapiro MD. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocr Pract. 2017 Jan; 23(1):100-112. PMID: 27819772.
      Citations: 19     Fields:    Translation:Humans
    74. Handelsman Y, Fain R, Wang Z, Li X, Fujioka K, Shanahan W. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746. PMID: 27659698.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    75. Sanon VP, Handelsman Y, Pham SV, Chilton R. Cardiac Manifestations of Congenital Generalized Lipodystrophy. Clin Diabetes. 2016 Oct; 34(4):181-186. PMID: 27766009; PMCID: PMC5070584.
      Citations: 12     
    76. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun; 22(6):753-62. PMID: 27082665.
      Citations: 142     Fields:    
    77. Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W, Consensus Conference Writing Committee. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Aug; 22(8):1008-21. PMID: 27214060.
      Citations: 76     Fields:    Translation:Humans
    78. Mechanick JI, Harrell RM, Allende-Vigo MZ, Alvayero C, Arita-Melzer O, Aschner P, Camacho PM, Castillo RZ, Cerdas S, Coutinho WF, Davidson JA, Garber JR, Garvey WT, Gonz?lez FJ, Granados DO, Hamdy O, Handelsman Y, Jim?nez-Navarrete MF, Lupo MA, Mendoza EJ, Jim?nez-Montero JG, Zangeneh F, American Association of Clinical Endocrinologists (AACE), American College of ENdocrinology (ACE). TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501. PMID: 27031655.
      Citations: 3     Fields:    Translation:Humans
    79. Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovic L, Roberts VL, Rodbard D, Tamborlane WV, Walsh J, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61. PMID: 26848630.
      Citations: 47     Fields:    Translation:Humans
    80. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE). CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113. PMID: 26731084.
      Citations: 173     Fields:    Translation:Humans
    81. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE). CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14. PMID: 26642101.
      Citations: 10     Fields:    Translation:Humans
    82. Bloomgarden ZT, Handelsman Y. Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan; 8(1):4-6. PMID: 26431291.
      Citations: 6     Fields:    Translation:Humans
    83. Bloomgarden ZT, Handelsman Y. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4. PMID: 26484408.
      Citations:    Fields:    Translation:Humans
    84. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despr?s JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67. PMID: 26314534.
      Citations: 143     Fields:    Translation:Humans
    85. Handelsman Y. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65. PMID: 26132997.
      Citations: 2     Fields:    Translation:Humans
    86. Einhorn D, Handelsman Y, Bode BW, Endahl LA, Mersebach H, King AB. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26. PMID: 26121451.
      Citations: 5     Fields:    Translation:Humans
    87. Grunberger G, Bailey T, Camacho PM, Einhorn D, Garber AJ, Handelsman Y, Harrell RM, Lando HM, Law B, Leffert JD, Orzeck EA, Glucose Monitoring Consensus Conference Writing Committee. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015 May; 21(5):522-33. PMID: 25962091.
      Citations: 10     Fields:    Translation:Humans
    88. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47. PMID: 25877012.
      Citations: 89     Fields:    Translation:Humans
    89. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr; 21 Suppl 1:1-87. PMID: 25869408; PMCID: PMC4959114.
      Citations: 259     Fields:    
    90. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract. 2015 Apr; 21(4):413-37. PMID: 27408942.
      Citations: 42     Fields:    Translation:Humans
    91. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G. American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocr Pract. 2014 Sep; 20(9):956-76. PMID: 25253226.
      Citations: 9     Fields:    
    92. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014 Sep; 20(9):977-89. PMID: 25253227; PMCID: PMC4962331.
      Citations: 56     Fields:    
    93. Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30. PMID: 25048383.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    94. Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovic L, Lane WS, Raskin P, Tamborlane WV, Rothermel C. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014 May; 20(5):463-89. PMID: 24816754.
      Citations: 57     Fields:    Translation:Humans
    95. Bloomgarden Z, Handelsman Y. Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3. PMID: 24656089.
      Citations: 1     Fields:    Translation:Humans
    96. Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92. PMID: 24246344.
      Citations: 19     Fields:    Translation:Humans
    97. Gregory RS, Handelsman Y, Pezalla EJ, Pikelny D. Practical perspectives on the management of overweight and obesity. Am J Manag Care. 2014 Mar; 20(3 Suppl):S64-75. PMID: 24773374.
      Citations: 1     Fields:    Translation:Humans
    98. Rodbard HW, Cariou B, Zinman B, Handelsman Y, Wolden ML, Rana A, Mathieu C. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72. PMID: 24495158; PMCID: PMC4237540.
      Citations: 2     Fields:    Translation:Humans
    99. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B, BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44. PMID: 24443830.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    100. Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skj?th TV, Rana A, Mathieu C, BEGIN Once Long trial investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304. PMID: 23952326; PMCID: PMC4208679.
      Citations: 36     Fields:    Translation:Humans
    101. Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G, Harrell RM, Gagel RF, Lebovitz HE, McGill JB, Hennekens CH. Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract. 2013 Jul-Aug; 19(4):675-93. PMID: 23978590.
      Citations: 27     Fields:    Translation:Humans
    102. Bloomgarden ZT, Drexler A, Einhorn D, Grunberger G, Guan Y, Handelsman Y, Hu JC, Li X, Liu J, Wang W, Weng J, Ning G. The Journal of diabetes: continuing the dialogue. J Diabetes. 2013 Jun; 5(2):95-6. PMID: 23489930.
      Citations:    Fields:    Translation:Humans
    103. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57. PMID: 23816937; PMCID: PMC4142590.
      Citations: 114     Fields:    Translation:Humans
    104. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH, American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36. PMID: 23598536.
      Citations: 142     Fields:    Translation:Animals
    105. Bloomgarden Z, Handelsman Y. Sugar-sweetened beverages: changing the tide. J Diabetes. 2013 Mar; 5(1):1-2. PMID: 23302538.
      Citations:    Fields:    Translation:Humans
    106. Garber AJ, Blonde L, Bloomgarden ZT, Handelsman Y, Dagogo-Jack S. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6. PMID: 23337160.
      Citations: 12     Fields:    Translation:Humans
    107. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C, American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013 Jan-Feb; 19(1):107-16. PMID: 23435042; PMCID: PMC4108221.
      Citations: 50     Fields:    Translation:Humans
    108. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C, NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71. PMID: 23043166; PMCID: PMC3507614.
      Citations: 127     Fields:    Translation:Humans
    109. McMahon MM, Hurley DL, Mechanick JI, Handelsman Y. American Association of Clinical Endocrinologists' position statement on clinical nutrition and health promotion in endocrinology. Endocr Pract. 2012 Sep-Oct; 18(5):633-41. PMID: 23047926.
      Citations: 4     Fields:    Translation:Humans
    110. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012 Sep-Oct; 18(5):642-8. PMID: 23047927.
      Citations: 53     Fields:    Translation:Humans
    111. Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR, Nagendran S. Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13. PMID: 22913889.
      Citations: 3     Fields:    Translation:Humans
    112. Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20. PMID: 22913890.
      Citations: 3     Fields:    Translation:Humans
    113. Bloomgarden Z, Handelsman Y. An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu. J Diabetes. 2012 Mar; 4(1):3. PMID: 22360791.
      Citations:    Fields:    Translation:Humans
    114. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93. PMID: 22507559.
      Citations: 31     Fields:    Translation:Humans
    115. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78. PMID: 22522068.
      Citations: 179     Fields:    Translation:Humans
    116. Bloomgarden Z, Handelsman Y. Did AIM-HIGH aim too low? J Diabetes. 2012 Mar; 4(1):1-2. PMID: 22141573.
      Citations: 3     Fields:    Translation:Humans
    117. Moses AC, Handelsman Y, Einhorn D. Effectiveness of primary care-relevant treatments for obesity in adults. Ann Intern Med. 2012 Feb 07; 156(3):248-9; author reply 249. PMID: 22312148.
      Citations:    Fields:    Translation:Humans
    118. Handelsman Y, Fonseca V, Rosenstock J. Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54. PMID: 22142158.
      Citations: 2     Fields:    Translation:HumansAnimals
    119. Bloomgarden Z, Handelsman Y, Einhorn D. Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60. PMID: 21951572.
      Citations:    Fields:    Translation:Humans
    120. Handelsman Y, Jellinger PS. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Aug; 13(8):613-20. PMID: 21806772; PMCID: PMC8108978.
      Citations: 4     Fields:    Translation:Humans
    121. Handelsman Y, Bloomgarden Z. Diabetes in youth: a dilemma of pathogenesis. J Diabetes. 2011 Jun; 3(2):91-2. PMID: 21599861.
      Citations:    Fields:    Translation:Humans
    122. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011 May; 34 Suppl 2:S244-50. PMID: 21525463; PMCID: PMC3632187.
      Citations: 29     Fields:    
    123. Handelsman Y. Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):221-3. PMID: 21466616; PMCID: PMC8673373.
      Citations: 1     Fields:    Translation:Humans
    124. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011 Mar-Apr; 17 Suppl 2:1-53. PMID: 21474420.
      Citations: 150     Fields:    Translation:Humans
    125. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011 Mar-Apr; 17(2):287-302. PMID: 21474421.
      Citations: 36     Fields:    Translation:Humans
    126. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011 Mar; 3(1):67-73. PMID: 20942846.
      Citations: 65     Fields:    Translation:Humans
    127. Handelsman Y. The role of bile acid sequestrants in the management of type 2 diabetes mellitus: summary and future directions. Metab Syndr Relat Disord. 2010 Dec; 8 Suppl 1:S23-4. PMID: 21142816.
      Citations:    Fields:    Translation:Humans
    128. Bloomgarden Z, Handelsman Y. The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2. PMID: 20923505.
      Citations:    Fields:    Translation:Humans
    129. Grunberger G, Bailey TS, Cohen AJ, Flood TM, Handelsman Y, Hellman R, Jovanovic L, Moghissi ES, Orzeck EA, AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010 Sep-Oct; 16(5):746-62. PMID: 21356638.
      Citations: 14     Fields:    Translation:Humans
    130. Bloomgarden ZT, Ning G, Drexler AJ, Guan YF, Handelsman Y, Li XY, Liu JM. Good news! J Diabetes. 2010 Sep; 2(3):127. PMID: 20923476.
      Citations:    Fields:    Translation:HumansAnimals
    131. Zhang Y, Ning G, Handelsman Y, Bloomgarden ZT. Gut hormones and the brain. J Diabetes. 2010 Sep; 2(3):138-45. PMID: 20923479.
      Citations: 2     Fields:    Translation:Humans
    132. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40. PMID: 20634175.
      Citations: 12     Fields:    Translation:Humans
    133. Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28. PMID: 20634176.
      Citations: 12     Fields:    Translation:Humans
    134. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92. PMID: 20415686; PMCID: PMC2871173.
      Citations: 39     Fields:    Translation:Humans
    135. Bloomgarden Z, Drexler A, Handelsman Y. Insulin treatment of Type 2 diabetes: a clinical perspective. J Diabetes. 2010 Jun; 2(2):65-6. PMID: 20923487.
      Citations:    Fields:    Translation:Humans
    136. Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010 Feb; 10(1):70-7. PMID: 20425070; PMCID: PMC2821506.
      Citations: 38     Fields:    Translation:HumansAnimals
    137. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63. PMID: 19789153.
      Citations: 15     Fields:    Translation:Humans
    138. Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9. PMID: 19940418.
      Citations: 1     Fields:    Translation:Humans
    139. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59. PMID: 19858063.
      Citations: 275     Fields:    Translation:Humans
    140. Bloomgarden Z, Handelsman Y. Cancer mortality and insulin glargine. J Diabetes. 2009 Sep; 1(3):131-3. PMID: 20923531.
      Citations: 1     Fields:    Translation:Humans
    141. Handelsman Y. The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6. PMID: 19494471.
      Citations:    Fields:    Translation:Humans
    142. Handelsman Y. The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24. PMID: 19494474.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    143. Handelsman Y. Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20. PMID: 19098117.
      Citations: 10     Fields:    Translation:Humans
    144. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct; 14(7):933-46. PMID: 18996826.
      Citations: 63     Fields:    Translation:Humans
    145. Hsueh WA, Handelsman Y. Pharmacologic treatment options for prediabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7):380-1. PMID: 18523427.
      Citations:    Fields:    Translation:HumansAnimals
    146. Handelsman Y. Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903. PMID: 18552752.
      Citations:    Fields:    Translation:HumansCells
    147. Jellinger PS, Davidson JA, Blonde L, Einhorn D, Grunberger G, Handelsman Y, Hellman R, Lebovitz H, Levy P, Roberts VL, ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8. PMID: 17599857.
      Citations: 24     Fields:    Translation:Humans
    148. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F, AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 May-Jun; 13 Suppl 1:1-68. PMID: 17613449.
      Citations: 212     Fields:    Translation:Humans
    149. Mechanick JI, Handelsman Y, Bloomgarden ZT. Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6. PMID: 17285009.
      Citations: 12     Fields:    Translation:Humans
    150. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM, ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006 Jan-Feb; 12 Suppl 1:6-12. PMID: 16627372.
      Citations: 20     Fields:    Translation:Humans
    151. Handelsman Y. Guest editorial. Metab Syndr Relat Disord. 2005; 3(4):281-3. PMID: 18370727.
      Citations:    Fields:    
    152. Handelsman Y, FACP, FACE. Treatment of the insulin resistance syndrome. Endocr Pract. 2003 Sep-Oct; 9 Suppl 2:99-104. PMID: 14698987.
      Citations:    Fields:    Translation:Humans
    153. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52. PMID: 12924350.
      Citations: 234     Fields:    Translation:Humans
    154. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL, Garber JR, Hamilton CR, Handelsman Y, Hellman R, Kukora JS, Levy P, Palumbo PJ, Petak SM, Rettinger HI, Rodbard HW, Service FJ, Shankar TP, Stoffer SS, Tourtelot JB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM. Endocr Pract. 2002 Nov; 8(6):457-469. PMID: 27762623.
      Citations: 3     Fields:    
    Handelsman's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (328)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _